Abstracts tagged "interleukins (IL) and matrix metalloproteinase (MMP)"

Abstract Number: 1124 • 2016 ACR/ARHP Annual Meeting
IL37 Rescues Human OA Cartilage Explants from GAG Release
Ellen van Geffen¹, Arjan van Caam², Henk van Beuningen², Elly Vitters², Esmeralda Blaney Davidson² and Peter M. van der Kraan², ¹Experimential Rheumatology, Radboud university medical center, Nijmegen, Netherlands, ²Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands
Background/Purpose: In healthy cartilage, there is a balance between anabolic and catabolic activities of chondrocytes that maintains the functional integrity of the extracellular matrix. However,…
Abstract Number: 1790 • 2012 ACR/ARHP Annual Meeting
Notch Promotes Matrix Metalloproteinase 13 Expression by Inducing Interleukin-6 in Primary Murine Chondrocytes
Stefano Zanotti and Ernesto Canalis, Research, Saint Francis Hospital and Medical Center, Hartford, CT
Background/Purpose: Notch1 to Notch4 are transmembrane receptors that determine cell differentiation and function. Interactions of Notch with its ligands result in the cleavage of the…
Abstract Number: 12 • 2012 ACR/ARHP Annual Meeting
Articular Cartilage Expresses the IL-15 Receptor Alpha-Chain and Responds to IL-15 with Increased Matrix Metalloproteinase Release
Anjali Nair¹, Michael Huvard², Madeline Rollins³, Arnavaz Hakimiyan⁴, Lev Rappaport⁴, Arkady Margulis⁴, Susanna Chubinskaya⁵ and Carla R. Scanzello⁶, ¹Section of Rheumatology, Rush University Medical Center, Chicago, IL, ²University of Illinois at Chicago, Chicago, IL, ³Northwestern University, Chicago, IL, ⁴Rush University Medical Center, Chicago, IL, ⁵Biochemistry, Rush University Medical Center, Chicago, IL, ⁶Rheumatology, Rush University Medical Center, Chicago, IL
Background/Purpose: IL-15, known for its effects on survival of lymphocyte subsets, plays a role in synovitis of Rheumatoid Arthritis. We reported that IL-15 is also…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].